ERBB2 and non-small cell lung carcinoma: The pivotal DESTINY-Lung 02 trial of T-DXd reported a 49% ORR, 9.9 months mPFS, and 19.5 months median overall survival (mOS) in HER2-mutant NSCLC (21).